Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DPX E7

Next Previous
Search
Drug Profile

DPX E7

Alternative Names: DPX-E7; HPV16-E711-19

Latest Information Update: 22 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunovaccine
  • Developer Avid Bioservices; Dana-Farber Cancer Institute; IMV
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Anal cancer; Cervical cancer; Head and neck cancer
  • No development reported Solid tumours

Most Recent Events

  • 09 Feb 2023 Dana-Farber Cancer Institute completes a phase I/II trial in Anal cancer, Cervical cancer and Head and neck cancer in USA (NCT02865135)
  • 01 Nov 2021 Phase-I/II development is till ongoing for Anal cancer, Cervical cancer and Head and neck cancer in USA (NCT02865135)
  • 28 Apr 2021 No recent reports of development identified for preclinical development in Solid-tumours(Combination therapy) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top